How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Fostamatinib for treating refractory chronic immune thrombocytopenia

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about fostamatinib

Marketing authorisation indication

2.1 Fostamatinib (Tavlesse, Grifols Institute) is indicated 'for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list prices of fostamatinib are:

  • £3,090 per 60-tablet pack, each tablet contains 100 mg of fostamatinib (excluding VAT; British National Formulary online, accessed October 2020)

  • £4,635 per 60-tablet pack, each tablet contains 150 mg of fostamatinib (excluding VAT; British National Formulary online, accessed October 2020).

    The company has a commercial arrangement, which would have applied if the technology had been recommended.